Responses
Clinical/translational cancer immunotherapy
Original research
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.